For years, the industry has attempted to solve the complex problem of underrepresentation in groups of people who are disproportionately burdened by some diseases. We also continue to seek the barriers. In this session, we will discuss some new ideas being piloted to solve complex issues of underrepresentation in trials and ways to build community relationships with promise, offer solutions for self-sustaining infrastructure, and consider how we may partner with other sponsors in a pre-competitive way.

Subsidiaries of a global pharmaceutical group can operate with the agility of a small biotech and the backing of an established parent. This session explores how clinical operations leaders can sustain that balance by defining decision rights, aligning priorities with parent-company functions, and building the credibility that makes enterprise resources accessible while maintaining the subsidiary's autonomy, speed, and identity.

Biotech is an exciting place where innovation is required throughout, so why should dashboards be any different?  In this session, we’ll discuss cultivating a data-literate, data-driven culture that starts the day in tailor-made operational data analytics. Imagine an environment where you don’t have to find, join, or calculate data, where exactly what you need is accessible every day. That’s more time to think and act. Let’s get talking about data.

AI is reshaping clinical research, but adoption without appropriate scrutiny can create as much risk as value. This sponsor-side session separates practical AI applications from vendor hype, exploring where AI can improve trial efficiency, oversight, and decision-making, and where it may introduce operational, quality, privacy, intellectual property, and regulatory risks. Attendees will examine the potential consequences of automation bias, inaccurate outputs, inadequate governance, and diminished human oversight, while gaining a practical framework for evaluating AI solutions based on measurable value, appropriate controls, and potential impact on trial execution.

As emerging biotech companies advance increasingly complex oncology portfolios, many rely heavily on outsourced partners to execute clinical operations and Risk-Based Quality Management (RBQM) activities. While outsourcing offers scalability and specialized expertise, sponsors remain accountable for trial quality, patient safety, and data integrity.

Monitoring visit reports are a critical component of clinical trial oversight, but manual review for completeness, quality, consistency, and compliance is time-consuming and subjective. This presentation will demonstrate how generative AI can be leveraged to perform automated quality checks, identify contradictions, assess documentation completeness, and support oversight professionals in conducting more efficient and consistent monitoring report reviews. Practical examples and implementation lessons learned will be shared.

Clinical trial data passes through many teams and systems before it becomes part of a regulatory submission. This presentation will focus on creating traceability from source/EDC through TLF/CSR; establishing cross-functional clinical-data governance; and preparing evidence continuously for submission and inspection, with a focus on reducing late-stage reconciliation and rework.

Alnylam's clinical operations evolved from early-phase, partnered development, to running large, independent phase 3 trials. This session traces that transition, examining the organizational, operational, and strategic shifts required to take ownership of late-stage execution. Attendees will gain candid insight into the challenges of scaling and what it takes to build the capability and confidence to lead pivotal programs independently.

Biotech companies must operate differently from large pharma—leaner teams, tighter budgets, greater agility, and smarter use of external partners. This session explores practical ways to combine human expertise, AI, automation, flexible workforce models, and vendor strategy to improve Clinical Operations execution without overbuilding infrastructure. Learn how to decide what to own, automate, outsource, and flex; use AI to reduce low-value work and improve decisions; strengthen procurement, vendor evaluation, and oversight; and build workforce models that preserve expertise while controlling costs.

Scaling late-stage clinical infrastructure requires emerging biopharma to balance global compliance with entrepreneurial agility. This presentation outlines the operational shift from Phase I/II flexibility to rigid Phase III execution. Learn to build a high-leverage hub-and-spoke resource model, deploy a strategic hybrid outsourcing framework, and manage complex global trial footprints. Discover how to leverage centralized cloud technologies to expand capacity without introducing costly bureaucratic bottlenecks.

Advancing a Phase 3 clinical program within a small biotech requires a fundamentally different operating model than that of large pharmaceutical organizations. This session explores practical and innovative approaches to maximizing limited resources, leveraging strategic partnerships, building agile teams, and prioritizing high-value activities. Attendees will learn how creative thinking, cross-functional collaboration, and disciplined decision-making can enable small biotechs to execute large, complex trials without compromising quality, timelines, or patient experience.